Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros

Banco de datos
Tipo del documento
Publication year range
1.
Cancer Sci ; 100(6): 996-1004, 2009 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-19385975

RESUMEN

Field cancerization currently described the theory of tumorigenesis and, until now, has been described in almost all organ systems except in liver. For this reason, we explore the presence of field cancerization in liver and its underlying clinical implication in hepatocellular carcinoma (HCC). In our study, methylation profile of HCC and surgically resected margin (SRM) were established by methylation-specific PCR. Liver cirrhosis (LC), chronic hepatitis and normal liver were treated in the same way as the background control. The correlation analysis among the methylation profile of HCC, SRM and clinicopathological data of HCC patients was made respectively. Our results showed that methylation abnormities related to HCC, but not background disease existed in histologically negative SRM. Monoclonal and polyclonal models may coexist in field cancerization in liver. Patients with RIZ1 methylation in SRM had a shorter disease free survival. The local recurrence trend of early and later recurrence in HCC is potentially related to a second field tumor. From these results, we can suggest that field cancerization exists in liver. The study of field cancerization in liver plays an important role in hepatocarcinogenesis. Second field tumor derived form field cancerization may have important implications in HCC prognosis assessment that is worthy of further study.


Asunto(s)
Carcinoma Hepatocelular/genética , Carcinoma Hepatocelular/cirugía , Metilación de ADN/genética , Neoplasias Hepáticas/genética , Neoplasias Hepáticas/cirugía , Secuencia de Bases , Cartilla de ADN , ADN de Neoplasias/genética , Progresión de la Enfermedad , Femenino , Genes APC , Antígenos de Superficie de la Hepatitis B/genética , Humanos , Neoplasias Hepáticas/patología , Masculino , Proteínas de Neoplasias/genética , Reacción en Cadena de la Polimerasa , Proteínas Supresoras de Tumor/genética
2.
Zhonghua Zhong Liu Za Zhi ; 30(10): 759-63, 2008 Oct.
Artículo en Zh | MEDLINE | ID: mdl-19173806

RESUMEN

OBJECTIVE: To investigate the practical possibility of inducing dendritic cells (DCs) from mononuclear cells in the lost blood during operation of hepatocellular carcinoma (HCC) patients, and attempted to find a new source of precursor cells for the personalized immunotherapy based on DCs. METHODS: Collected lost blood during hepatectomy from 9 HCC patients and human cord blood from 8 cases of healthy donors undergoing caesarean section. Their mononuclear cells were divided into monocytes and nonadherent lymphocytes. RhGM-CSF and rhIL-4 were administered to induce the monocytes differentiation into DCs, and then loaded with different antigens (lysate antigen of autologous liver cancer cells and cell line SMMC-7721 cells). The lymphocytes were induced into cytokine-induced killer cells (CIK) with IL-2, CD3-Ab, gamma-IFN and PHA. MTT assay was performed to detect the proliferation rate of T lymphocytes mediated by DC and the cytotoxicity of CIK to liver cancer cells. RESULTS: DCs induced from monocytes of the intra-operative lost blood possessed typical morphology and phenotypes. Compared with the DCs from cord blood, the DCs from intra-operative lost blood expressed lower level of surface markers, but both could effectively induce proliferation of CIK and enhance the cytotoxicity of activated CIK against liver cancer cells at similar levels. When the DCs from lost blood and their counterpart from cord blood were both loaded with autologous tumor cell antigen, the proliferation rates of CIK were (388.9 +/- 137.3)% and (315.1 +/- 44.5)%, respectively, and the killing rates against tumor cells were (87.1 +/- 8.0)% and (90.0 +/- 5.1)%, respectively. When the two similar DC groups were loaded with lysate antigen of SMMC-7721 cells, the proliferation rates of CIK were (239.9 +/- 48.7)% and (226.3 +/- 32.3)%, respectively, and the killing rates against tumor cells were (76.4 +/- 7.9)% and (81.1 +/- 4.3)%, respectively. There were no significant differences between those two DC groups. The data also showed that the proliferation and cytotoxicity of CIK induced by DCs loaded with autologous antigen were higher than that of DCs loaded with SMMC-7721 antigen. CONCLUSION: Mononuclear cells separated from intra-operative lost blood of HCC patients can be induced into mature DCs, which can effectively activate CIK and significantly increase its killing effect on the liver cancer cells, and may become a new source of DCs to study and develop vaccines for clinical application.


Asunto(s)
Células Asesinas Inducidas por Citocinas/inmunología , Citocinas/metabolismo , Células Dendríticas/inmunología , Neoplasias Hepáticas/inmunología , Pérdida de Sangre Quirúrgica , Muerte Celular , Línea Celular Tumoral , Proliferación Celular , Células Asesinas Inducidas por Citocinas/citología , Células Asesinas Inducidas por Citocinas/metabolismo , Citotoxicidad Inmunológica/inmunología , Células Dendríticas/citología , Células Dendríticas/metabolismo , Sangre Fetal , Humanos , Neoplasias Hepáticas/sangre , Neoplasias Hepáticas/patología , Neoplasias Hepáticas/cirugía , Células Tumorales Cultivadas
3.
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi ; 25(3): 597-9, 2008 Jun.
Artículo en Zh | MEDLINE | ID: mdl-18693438

RESUMEN

In this paper, we address the preparation of the EPC and HEPC sterically stabilized doxorubicin liposomes and report the data collected from further studies on pharmacokinetics in blood for choosing a better carrier in delivering the drugs. The pharmacokinetics of EPC and HEPC sterically stabilized liposomes (EPC-SSL, and HEPC-SSL) in Wistar rats were investigated by HPLC. The results showed that the mean residence time of HEPC-SSL in blood is 23.3 h, while that of EPC-SSL is 12.0 h. In conclusion, HEPC-SSL is a better carrier in delivering the drugs to the extravascular sites when compared with EPC-SSL.


Asunto(s)
Preparaciones de Acción Retardada/síntesis química , Doxorrubicina/administración & dosificación , Doxorrubicina/farmacocinética , Portadores de Fármacos/química , Fosfatidilcolinas/farmacología , Animales , Antibióticos Antineoplásicos/administración & dosificación , Antibióticos Antineoplásicos/farmacocinética , Preparaciones de Acción Retardada/farmacocinética , Hidrogenación , Liposomas , Fosfatidilcolinas/química , Ratas
4.
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi ; 22(5): 1031-5, 2005 Oct.
Artículo en Zh | MEDLINE | ID: mdl-16294747

RESUMEN

To retain the anti-rheumatoid arthritis activity of melittin and to reduce the hemolysis and hypersusceptibility caused by melittin, a deletion peptide of melittin was synthesized. Its ant-inflammation effect was observed . A hydrophile peptide fragment of melittin was synthesized by standard solid-phase method. The product was analyzed by HPLC and MS. The relevant hemolysis and hypersusceptibility were tested. The rabbits' model of immune arthritis were established and treated. The results showed that the hemolysis rate for peptide fragment was less than 5%, the hypersusceptibility rate was less than 8%. The hydrophile peptide fragment of melittin may retain anti-rheumatoid arthritis activity and reduce the melittin-induced hemolysis and hypersusceptibility.


Asunto(s)
Artritis Reumatoide/terapia , Meliteno/síntesis química , Fragmentos de Péptidos/síntesis química , Animales , Meliteno/uso terapéutico , Fragmentos de Péptidos/uso terapéutico , Conejos
5.
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi ; 20(1): 135-8, 2003 Mar.
Artículo en Zh | MEDLINE | ID: mdl-12744184

RESUMEN

This paper reviews the development of the polyanhydrides as a new biodegradable polymer, and highlights the methodological and technological progress in the synthesis of the polymer. Subsequently, the future researches and developments of polyanhydrides are prospected.


Asunto(s)
Anhídridos , Materiales Biocompatibles , Sistemas de Liberación de Medicamentos , Polímeros , Anhídridos/síntesis química , Animales , Materiales Biocompatibles/síntesis química , Neoplasias Encefálicas/tratamiento farmacológico , Preparaciones de Acción Retardada , Diabetes Mellitus/tratamiento farmacológico , Portadores de Fármacos , Glioma/tratamiento farmacológico , Humanos , Osteomielitis/tratamiento farmacológico , Polímeros/síntesis química , Ratas
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda